Evidence map›Paper›PMID 27239787›Full record

ArticleNature chemical biology2016

Zebrafish behavioral profiling identifies multitarget antipsychotic-like compounds.

Giancarlo Bruni, Andrew J Rennekamp, Andrea Velenich, Matthew McCarroll, Leo Gendelev, Ethan Fertsch, Jack Taylor, Parth Lakhani, Dennis Lensen, Tama Evron and 10 more

Abstract read
In one paragraph

Article in Nature chemical biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Disruption ofThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Article
  17. Article
  18. Behavioral Profiling in Zebrafish Identifies Insecticide-Related Compounds.Journal of agricultural and food chemistry · 2025
    Article
  19. Article
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Giancarlo BruniCardiovascular Research Center, Massachusetts General Hospital, Charlestown, Massachusetts, USA.ORCID 0000-0003-2850-4633
Andrew J RennekampCardiovascular Research Center, Massachusetts General Hospital, Charlestown, Massachusetts, USA.ORCID 0000-0001-6174-7253
Andrea VelenichTeleos Therapeutics, Medford, Massachusetts, USA.
Matthew McCarrollDepartment of Physiology, University of California, San Francisco, San Francisco, California, USA.
Leo GendelevInstitute for Neurodegenerative Disease, University of California, San Francisco, San Francisco, California, USA.
Ethan FertschDepartment of Physiology, University of California, San Francisco, San Francisco, California, USA.
Jack TaylorDepartment of Physiology, University of California, San Francisco, San Francisco, California, USA.
Parth LakhaniDepartment of Physiology, University of California, San Francisco, San Francisco, California, USA.
Dennis LensenTeleos Therapeutics, Medford, Massachusetts, USA.
Tama EvronTeleos Therapeutics, Medford, Massachusetts, USA.
Paul J LorelloNeuroBehavior Laboratory, Harvard NeuroDiscovery Center, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Xi-Ping HuangDepartment of Pharmacology, University of North Carolina Chapel Hill Medical School, Chapel Hill, North Carolina, USA.
Sabine KolczewskiRoche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Galen CareyTeleos Therapeutics, Medford, Massachusetts, USA.
Barbara J CaldaroneNeuroBehavior Laboratory, Harvard NeuroDiscovery Center, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Eric PrinssenRoche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Bryan L RothDepartment of Pharmacology, University of North Carolina Chapel Hill Medical School, Chapel Hill, North Carolina, USA.
Michael J KeiserInstitute for Neurodegenerative Disease, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-1240-2192
Randall T PetersonCardiovascular Research Center, Massachusetts General Hospital, Charlestown, Massachusetts, USA.
David KokelDepartment of Physiology, University of California, San Francisco, San Francisco, California, USA.

Funding

MULTIDISCIPLINARY RESEARCH TRAINING IN CARDIOLOGYT32HL007208 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI Patrick Thomas Ellinor, David E Sosnovik · 1985 to 2026
$16.1M
STRUCTURAL BIOLOGY TRAINING PROGRAMT32GM008284 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KORTEMME, TANJA · 1988 to 2022
$10.1M
Integrative Program in Complex Biological System (ipCBS)T32EB009383 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARSHALL, WALLACE, WEINER, ORION D · 2009 to 2022
$3.2M
Behavior-based chemical screening for GABAergic and startle modifying drugsR01AA022583 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KOKEL, DAVID · 2013 to 2017
$1.6M
Scalable in vivo tools for annotating and manipulating the druggable genomeU01MH105027 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI KOKEL, DAVID, YEH, JING-RUEY JOANNA · 2014 to 2016
$1.5M
In Vivo Discovery of Psychotropic Drugs by High-Throughput Behavioral PhenotypingR01MH086867 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI PETERSON, RANDALL T · 2009 to 2012
$1.4M
High-throughput behavior-based dopaminergic drug discovery in the zebrafishK01MH091449 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KOKEL, DAVID · 2010 to 2014
$931k
A platform to predict side-effect targets for drugsR44GM093456 · NIGMS · SEACHANGE PHARMACEUTICALS, INC. · PI HODGE, CARL NICHOLAS, KEISER, MICHAEL JAMES · 2013 to 2014
$910k
High-throughput behavioral screening for in vivo discovery of neuroactive drugsR21MH085205 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI PETERSON, RANDALL T · 2009 to 2009
$265k
NHLBI NIH HHS T32 HL007208NIAAA NIH HHS R01 AA022583NIBIB NIH HHS T32 EB009383NIGMS NIH HHS R44 GM093456NIGMS NIH HHS T32 GM008284NIMH NIH HHS K01 MH091449NIMH NIH HHS R01 MH086867NIMH NIH HHS R21 MH085205NIMH NIH HHS U01 MH105027
6 · The paper itself

Abstract

Many psychiatric drugs act on multiple targets and therefore require screening assays that encompass a wide target space. With sufficiently rich phenotyping and a large sampling of compounds, it should be possible to identify compounds with desired mechanisms of action on the basis of behavioral profiles alone. Although zebrafish (Danio rerio) behavior has been used to rapidly identify neuroactive compounds, it is not clear what types of behavioral assays would be necessary to identify multitarget compounds such as antipsychotics. Here we developed a battery of behavioral assays in larval zebrafish to determine whether behavioral profiles can provide sufficient phenotypic resolution to identify and classify psychiatric drugs. Using the antipsychotic drug haloperidol as a test case, we found that behavioral profiles of haloperidol-treated zebrafish could be used to identify previously uncharacterized compounds with desired antipsychotic-like activities and multitarget mechanisms of action.

Indexed as

ZebrafishAnimalsAntipsychotic AgentsBehavior, AnimalLarvaMiceMolecular StructureAntipsychotic Agents

Identifiers

PMID27239787
PMCPMC4912417

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.